Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Enzo Biochem Inc (NYSE:ENZ)

6.81
Delayed Data
As of 2:29pm ET
 -0.07 / -1.02%
Today’s Change
4.00
Today|||52-Week Range
7.51
-1.87%
Year-to-Date
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
9:30am / Zacks.com - Paid Partner Content
Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit
Jan 18 / Zacks.com - Paid Partner Content
Allergan's Uterine Fibroids Candidate Positive in Phase III
Jan 18 / Zacks.com - Paid Partner Content
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
Jan 12 / Zacks.com - Paid Partner Content
Concert Offers Update on Cystic Fibrosis Drug, Stock Down
Jan 18 / Zacks.com - Paid Partner Content
Amgen: Phase III Data on Hyperparathyroidism Drug Published
Jan 11 / Zacks.com - Paid Partner Content
Jazz Begins Phase III Study for Label Expansion of Defitelio
Jan 18 / Zacks.com - Paid Partner Content
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
Jan 10 / Zacks.com - Paid Partner Content
Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
Jan 18 / Zacks.com - Paid Partner Content
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
Jan 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close6.88
Today’s open6.90
Day’s range6.76 - 6.96
Volume68,978
Average volume (3 months)166,792
Market cap$318.5M
Dividend yield--
Data as of 2:29pm ET, 01/19/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+20.00%
Earnings growth (next 5 years)--
Revenue growth (last year)+5.30%
P/E ratio8.1
Price/Sales3.16
Price/Book3.55

Competitors

 Today’s
change
Today’s
% change
PTIProteostasis Therape...-0.58-4.63%
NVTAInvitae Corp-0.28-3.36%
RDNTRadNet Inc-0.15-2.46%
FLGTFulgent Genetics Inc-0.07-0.53%
Data as of 2:34pm ET, 01/19/2017

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$102.8M
Annual profit (last year)$45.3M
Net profit margin44.06%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Executive Officer &
Secretary
Elazar Rabbani
President, CFO, Treasurer &
Class II Director
Barry W. Weiner
Corporate headquarters
New York, New York

Forecasts


Search for Jobs